Related Experiment Video
Updated: Jul 19, 2026

Intracerebroventricular Treatment with Resiniferatoxin and Pain Tests in Mice
Published on: September 2, 2020
TRPV1: a therapeutic target for novel analgesic drugs?
Arpad Szallasi1, Francisco Cruz, Pierangelo Geppetti
1Departments of Pathology, Monmouth Medical Center, Long Branch, NJ 07740, USA. aszallasi@sbhcs.com
Abstract:
The vanilloid receptor TRPV1 is now recognized as a molecular integrator of painful stimuli ranging from noxious heat to endovanilloids in inflammation. Pharmacological blockade of TRPV1 represents a new strategy in pain relief. TRPV1 antagonists are expected to prevent pain by silencing receptors where pain is generated rather than stopping the propagation of pain, as most-traditional pain killers do. This hypothesis has already being tested in the clinic by administering small molecule TRPV1 antagonists (e.g. GlaxoSmithKline SB-705498) for migraine and dental pain. Paradoxically, in some murine models of chronic pain, TRPV1-deficient mice exhibit more pain-related behavior than their wild-type littermates, indicating that the understanding of TRPV1 in pain is still incomplete. Moreover, there is mounting evidence to suggest the existence of functional TRPV1 both in the brain and in various non-neuronal tissues. The biological role of these receptors remains elusive, but their tissue distribution clearly indicates that they are involved in many more functions than just pain perception. Here, we review the potential therapeutic indications and adverse effects of TRPV1 antagonists.
Insights
TRPV1 antagonists offer novel pain relief by targeting pain generation. However, their role in chronic pain and non-neuronal tissues requires further investigation for broader therapeutic applications.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- The vanilloid receptor TRPV1 integrates painful stimuli, including heat and inflammation.
- TRPV1 antagonists represent a new pain relief strategy, targeting receptors at the pain source.
Purpose of the Study:
- To review potential therapeutic indications and adverse effects of TRPV1 antagonists.
- To discuss the incomplete understanding of TRPV1's role in pain and its broader functions.
Main Methods:
- Literature review of TRPV1 antagonist research.
- Analysis of clinical trial data and murine models.
Main Results:
- TRPV1 antagonists are being tested for migraine and dental pain.
- TRPV1-deficient mice show paradoxical pain behaviors in some chronic pain models.
- Evidence suggests TRPV1's presence and function in the brain and non-neuronal tissues.
Conclusions:
- TRPV1 antagonists have potential therapeutic uses beyond pain relief.
- Further research is needed to elucidate TRPV1's complex roles and optimize antagonist therapies.
Related Concept Videos
Analgesia and Pain Management
Thermosensation
Opioid Receptors: Overview
Nociception
Pain
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
